All Posts Tagged Tag: ‘Pharmaceuticals’

$650 Million Settlement Reached in Pradaxa Lawsuit

Boehringer Ingelheim Pharmaceuticals this week agreed to a settlement in the multi-district litigation over the drug Pradaxa. The company has agreed to pay $650 million to settle the lawsuits. Much of that money will be used to compensate patients who claim they were injured by Pradaxa. Around 1,600 people had filed individual lawsuits against Boehringer Ingelheim over Pradaxa as of …

Read More

Multiple Sclerosis Drug Delayed by FDA

Biogen Idec Inc. has stated that the U.S. Food and Drug Administration extended the review process its multiple sclerosis drug called Plegridy by three months to evaluate the application, though the FDA didn’t request any further studies. Biogen had planned to launch the new drug sometime in mid-2014, but is now delayed. Plegridy is an injectable medication designed to reduce …

Read More

New Painkiller Zohydro: What Parents And Patients Need To Know

Painkiller junkies who’ve diligently done research are anxiously awaiting the arrival of a pill called Zohydro. Meanwhile, a well-meaning coalition of health professionals is also anticipating – the imminent demise of such existing abusers and legitimate patients alike. They are trying their hardest to prevent such tragedy from unfolding right up until the last minute, as the drug is set …

Read More

FDA Implements Pilot Program For Fast-Track Drug Importation

The U.S. Food and Drug Administration (FDA) today announced that it has begun its two-year Secure Supply Chain Pilot Program. The program is meant to streamline some drug importation for select companies so that the FDA can focus its resources on more high-risk illegal importation. Following the two-year program the FDA will evaluate its success and possibly make it permanent, …

Read More

Depression Drug Vyvanse Sent Back To Drawing Board

The pharmaceutical group Shire has decided to stop developing the drug Vyvanse for use to treat depression. The Amphetamine-based Vyvanse is a popular ADHD drug, having made over $1.2 billion dollars for related therapy last year. However, Shire was hoping that the drug would work for patients suffering from depression. Unfortunately for Shire, the drug failed to improve symptoms for …

Read More

Johnson & Johnson to Pay $2.2 Billion Over Risperdal Claims

The U.S. Department of Justice and the U.S. Food and Drug Administration (FDA) today announced that Janssen Pharmaceuticals has plead guilty over the misbranding of the drug Risperdal. Janssen and its company, Johnson & Johnson, will pay a total of $2.2 billion to settle the matter. Around $485 million of the amount will be paid in the form of a …

Read More

Merck Job Cuts On the Rise, Cuts Could Prove Beneficial

For months, the struggling New Jersey- based pharmaceutical conglomerate has been struggling, and the numbers they’ve been producing have only made their financial woes more evident. But, yesterday the company set a new plan of action in motion. Merck & Co. announced in a press release on Tuesday that they would be eliminating approximately 20% of their work force. The …

Read More

Purdue, Maker of OxyContin, Keeps a List of Bad Docs

Earlier this year, the FDA made headlines when it prevented pharmaceutical giant Purdue Pharma from continuing to produce generic and crushable versions of the popular opioid OxyContin. The New York Times took note that the company had chosen the opportune moment to release its new tamper-resistant formula: right before the patent on the old formula expired. On Sunday, Purdue Pharma, …

Read More

Cholesterol Drug Tredaptive Pulled Worldwide

Less than one month ago, Merck, a major U.S. pharmaceutical company, announced that its cholesterol drug Tredaptive failed a major clinical trial. The drug is meant to improve heart health by increasing levels of “good” cholesterol, but the trial found that patients on the drug did not have a reduced risk of heart attack, stroke, necessary bypass surgery, or death, …

Read More

Diabetes Drug Approved by U.S. FDA Committee

A U.S. Food and Drug Administration (FDA) committee this week approved the drug canagliflozin for the treatment of adults with type 2 diabetes. The Endrocrinologic and Metabolic Drugs Advisory Committee of the FDA voted 10 to 5 to approve the drug. Canagliflozin, which Johnson & Johnson has given the proposed trade name of Invokana, will, if further approved by the …

Read More

Diabetes Drug Works Differently Than Was Previously Thought

For half a century one of the most popular and most-prescribed classes of diabetes drugs has been biguanides, which includes the drug metformin. Metformin helps to keep liver glucose output in check, which, in turn, keeps blood sugar down in type 2 diabetes patients. Until now, however, doctors weren’t exactly sure how metformin, was accomplishing this feat. “Overall, metformin lowers …

Read More

Stroke Medication Approved by the U.S. FDA

A new anti-clotting drug has been approved by the U.S. Food and Drug Administration. Called apixaban and marketed by Bristol-Myers Squibb and Pfizer as Eliquis, the drug has been approved to reduce the risk of stroke and blood clots for patients with an irregular heart beat that is not caused by a heart valve problem. “Blood clots in the heart …

Read More

Page 1 of 3123»